219635-91-3

Usage

Uses

Used in Pharmaceutical Industry:
CHEMBRDG-BB 4012280 is used as a therapeutic agent for the treatment of autoimmune and inflammatory diseases. Its inhibition of JAK1 may help in managing the symptoms and progression of these conditions by modulating the JAK/STAT signaling pathway, which is often dysregulated in such diseases.
Used in Oncology:
CHEMBRDG-BB 4012280 is used as an anticancer agent, targeting the JAK/STAT signaling pathway that is frequently implicated in the growth and progression of various types of cancer. By inhibiting JAK1, it may help in controlling tumor growth and potentially enhancing the effectiveness of existing cancer treatments.
Used in Drug Development:
CHEMBRDG-BB 4012280 serves as a lead compound in the development of novel targeted therapies. Its selective action on the JAK/STAT signaling pathway makes it a valuable asset in the creation of new drugs that can offer more precise treatments with fewer side effects for patients suffering from autoimmune, inflammatory, and neoplastic conditions.

InChI:InChI=1/C9H12BrN3/c10-8-2-1-3-9(12-8)13-6-4-11-5-7-13/h1-3,11H,4-7H2

Upstream product

• 854159-21-0 1-(6-bromo-2-pyridyl)-4-tritylpiperazine 
• 854159-11-8 1-(2-pyridyl)-4-tritylpiperazine 
• 34803-66-2 1-(2-pyridyl)piperazine 

Downstream Products

• 1016167-60-4 C₁₇H₁₈BrN₅ 
• 1608496-76-9 C₁₉H₂₂N₄O 

Relevant academic research and scientific papers

N?-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiling

Transglutaminase 2 (TGase 2)-catalyzed transamidation represents an important post-translational mechanism for protein modification with implications in physiological and pathophysiological conditions, including fibrotic and neoplastic processes. Consequently, this enzyme is considered a promising target for the diagnosis of and therapy for these diseases. In this study, we report on the synthesis and kinetic characterization of N?-acryloyllysine piperazides as irreversible inhibitors of TGase 2. Systematic structural modifications on 54 new compounds were performed with a major focus on fluorine-bearing substituents due to the potential of such compounds to serve as radiotracer candidates for positron emission tomography. The determined inhibitory activities ranged from 100 to 10?000 M-1 s-1, which resulted in comprehensive structure-activity relationships. Structure-activity correlations using various substituent parameters accompanied by covalent docking studies provide an advanced understanding of the molecular recognition for this inhibitor class within the active site of TGase 2. Selectivity profiling of selected compounds for other transglutaminases demonstrated an excellent selectivity toward transglutaminase 2. Furthermore, an initial pharmacokinetic profiling of selected inhibitors was performed, including the assessment of potential membrane permeability and liver microsomal stability.

Synthesis, radiofluorination, and in vitro evaluation of pyrazolo[1,5-a]pyridine-based dopamine D4 receptor ligands: Discovery of an inverse agonist radioligand for PET

A series of fluoro-substituted analogs structurally derived from the aminomethyl-substituted pyrazolo[1,5-a]pyridine lead compounds 9 (FAUC 113) and 10 (FAUC 213) were synthesized and evaluated as high-affinity D4 receptor (D4R) ligands (3a-3h, Ki = 1.3-28 nM). The para-fluoroethoxy-substituted derivatives 3f and 3h revealed an outstanding D4 subtype selectivity of more than 3 orders of magnitude over both congeners D2 and D3 combined with inverse agonism at D4R. The corresponding 18F-labeled radioligands revealed high serum stability in vitro and log P values of 2-3. In vitro rat brain autoradiography showed specific binding of [18F]3h in distinct brain regions, including the gyrus dentate of the hippocampus, that were inhibited by both eticlopride (65-80%) and the selective D4R antagonist 10 (78-93%). The observed binding pattern was mainly consistent with the known D4R distribution in the rat brain. Thus, [18F]3h (FAUC F41) represents a potential radioligand for studying the D4R in vivo by positron emission tomography (PET).

First selective lithiation of pyridylpiperazines: Straightforward access to potent pharmacophores

The three isomers of pyridylpiperazines have been lithiated for the first time. The use of a superbase, an aminoalkoxide containing lithiating agent overcomes the chelating influence of the basic piperazine nitrogens, so that selective mono lithiation occurred alpha to pyridine nitrogen. This methodology offers a new access to diverse potent pharmacophores not easily prepared by other routes.

PHENYLPYRIDINE CARBONYL PIPERAZINE DERIVATIVE

The present invention relates to a compound which is represented by the following general formula and has type 4 phosphodiesterase inhibitory action, and uses and an intermediate compound thereof. (whereinR1, R2: hydrogen, a halogen, a lower alkyl, a lower alkoxy, or the like,R3, R4: hydrogen, a (substituted) lower alkyl, a halogen, or the like,R5: hydrogen, a lower alkyl, a lower alkoxycarbonyl, or the like, andn: 0 or 1).